A Study to Assess the Impact of Omalizumab on Exercise Capacity, Physical Activity, and Sleep Quality in Participants With Moderate to Severe Allergic Asthma

Exclusion Criteria

• •Known history of anaphylaxis/hypersensitivity to omalizumab
• •Treatment with investigational drugs within 12 weeks or 5 half-lives (whichever is longer) prior to screening
• •Treatment with monoclonal antibodies (e.g., omalizumab, mepolizumab, dupilumab) for 6 months prior to screening
• •Maintenance oral corticosteroid therapy, defined as daily or alternate-day oral corticosteroid within 3 months prior to screening or during the screening period
• •Treatment with systemic (oral, IV, or IM) corticosteroids within 4 weeks prior to screening or during the screening period
• •Isolated diagnosis of exercise induced asthma without chronic symptoms
• •History of interstitial lung disease, COPD, or other clinically significant lung disease other than asthma
• •Current malignancy or history of malignancy within 5 years prior to screening
• •Unable to complete cardiopulmonary exercise testing and/or perform physical activity due to underlying cardiac, neurologic or orthopedic conditions
• •Ongoing physician-treated sleep disorder that is unrelated to asthma within 6 months prior to screening
• •Current smoker or past smoker with \>10 pack years
• •Known HIV infection at screening
• •Known acute or chronic infections with hepatitis C virus (HCV) and hepatitis B virus (HBV) at screening
• •Infection that resulted in hospital admission, required treatment with intravenous or intramuscular antibiotics within 4 weeks prior to screening, or any active infection that required treatment with oral antibiotics within 2 weeks prior to screening
• •Active tuberculosis requiring treatment within 12 months prior to screening
• •History of alcohol, drug, or chemical abuse within 6 months of screening